Elekta (OTCMKTS:EKTAY) Trading Up 14.1% – Should You Buy?

Elekta AB (OTCMKTS:EKTAY)’s share price traded up 14.1% during trading on Friday . The stock traded as high as $6.6910 and last traded at $6.6910. 370 shares were traded during trading, a decline of 87% from the average session volume of 2,746 shares. The stock had previously closed at $5.8650.

Elekta Price Performance

The company has a debt-to-equity ratio of 0.66, a current ratio of 1.04 and a quick ratio of 0.79. The stock has a fifty day simple moving average of $6.30 and a 200-day simple moving average of $5.59. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -668.43 and a beta of 1.07.

Elekta (OTCMKTS:EKTAY) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.09 EPS for the quarter. Elekta had a negative net margin of 0.08% and a positive return on equity of 12.72%. The business had revenue of $433.29 million for the quarter. On average, equities research analysts anticipate that Elekta AB will post 0.36 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.